Morningstar

Akebia Therapeutics Inc AKBA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.34 +0.06 (4.69%)
View Full Chart
As of Delayed Price Pre-Open: $1.33 −0.01

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
AKBA is trading within a range we consider fairly valued.
Price
$1.33
Fair Value
$8.32
Uncertainty
Very High
1-Star Price
$4.56
5-Star Price
$7.26
Economic Moat
Xxz
Capital Allocation
—

News

View All

Trading Information

Previous Close Price
$1.28
Day Range
$1.26–1.34
52-Week Range
$0.78–2.48
Bid/Ask
$1.29 / $1.34
Market Cap
$281.79 Mil
Volume/Avg
2,455 / 2.0 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
1.52
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
167
Website
https://www.akebia.com

Comparables

Valuation

View More
Metric
AKBA
TVTX
AVIR
Price/Earnings (Normalized)
 ———
Price/Book Value
 —70.010.60
Price/Sales
 1.526.00—
Price/Cash Flow
 25.97——
Price/Earnings
AKBA
TVTX
AVIR

Financial Strength

Metric
AKBA
TVTX
AVIR
Quick Ratio
 0.652.8918.87
Current Ratio
 1.043.0419.02
Interest Coverage
 −4.41−35.20—
Quick Ratio
AKBA
TVTX
AVIR

Profitability

Metric
AKBA
TVTX
AVIR
Return on Assets (Normalized)
 −14.83%−9.03%−23.62%
Return on Equity (Normalized)
 —−47.00%−25.11%
Return on Invested Capital (Normalized)
 −138.34%−13.68%−29.21%
Return on Assets
AKBA
TVTX
AVIR

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
MskjrkvkkDmk$87.2 Bil
 Merck KGaA ADR
MKKGY
XbnbpmqkBbgzcs$75.7 Bil
 Haleon PLC ADR
HLN
YgyhdzzbkLdcv$47.3 Bil
 Teva Pharmaceutical Industries Ltd ADR
TEVA
JdytchylZjsls$20.0 Bil
 Viatris Inc
VTRS
FgzdnwgtdTwrm$13.7 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
YxhztmlRxkd$13.4 Bil
 Catalent Inc
CTLT
MtdylpdkPbblqn$11.0 Bil
 Prestige Consumer Healthcare Inc
PBH
QjswctslFnxjqyd$3.5 Bil
 Perrigo Co PLC
PRGO
WzlnvjxgtZwkf$3.4 Bil
 Green Thumb Industries Inc
GTBIF
NtmsvlbjqBnvxr$2.4 Bil

Sponsor Center